The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

MannKind Corporation (NASDAQ:MNKD) is among the hidden penny stocks to invest in. On June 1, Wells Fargo lifted the price target on MannKind Corporation (NASDAQ:MNKD) to $11 from $10 and reiterated an Overweight rating. The firm associated this target hike with Afrezza’s approval in pediatric patients, saying that the company’s commercial potential is a “show-me story.”

The FDA approval of Afrezza Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes is strengthened by results from the pivotal INHALE-1 clinical trial. This announcement on May 29 extends Afrezza’s availability beyond adults, now catering to pediatric patients and caregivers as well. No wonder MannKind Corporation (NASDAQ:MNKD) is among the hidden penny stocks to invest in.

Copyright: dolgachov / 123RF Stock Photo

During its Q1 2026 earnings call, MannKind Corporation (NASDAQ:MNKD) outlined the potential to receive up to $35 million in development milestones, in addition to a 10% royalty on net sales. What’s even more impressive is the company’s position as the sole manufacturer of Tyvaso DPI under a supply agreement. Highlighting the company’s strengths, CEO Michael Castagna said,

“The company is fundamentally different than it was even a few years ago. We are excited about the near-term milestones that will further advance the company’s evolution.”

MannKind Corporation (NASDAQ:MNKD) is a Connecticut-based biopharmaceutical company that specializes in chronic disease care. Incorporated in 1991, the company provides solutions for serious conditions, such as diabetes, pulmonary hypertension, and fluid overload.

While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.